Monopar Therapeutics Inc MNPR.OQ MNPR.O is expected to show no change in quarterly revenue when it reports results on August 7 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Monopar Therapeutics Inc is for a loss of 47 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Monopar Therapeutics Inc is $71.00, about 41.2% above its last closing price of $41.75
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.69 | -0.68 | -0.38 | Beat | 44.1 |
Dec. 31 2025 | -0.42 | -2.75 | Missed | -554.8 | |
Sep. 30 2024 | -0.48 | -0.48 | -0.37 | Beat | 22.4 |
Jun. 30 2024 | -0.47 | -0.47 | -0.50 | Missed | -7.1 |
Mar. 31 2024 | -0.60 | -0.60 | -0.50 | Beat | 16.7 |
Dec. 31 2023 | -0.77 | -0.60 | Beat | 22.6 | |
Sep. 30 2023 | -0.75 | -0.85 | -0.70 | Beat | 17.6 |
Jun. 30 2023 | -0.89 | -0.92 | -0.80 | Beat | 13 |
This summary was machine generated August 5 at 13:16 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)